

1 **Controlled Avalanche – A Regulated Voluntary Exposure Approach for Addressing**  
2 **Covid-19**

3 Eyal Klement<sup>1\*£</sup> DVM, Alon Klement<sup>2</sup> SJD, David Chinitz<sup>3</sup> PhD, Alon Harel<sup>4</sup> Dphil, Eyal  
4 Fattal<sup>5</sup> PhD, Ziv Klausner<sup>5</sup> PhD

5

- 6 1. Koret School of Veterinary Medicine, Department of Epidemiology and Public  
7 Health, the Hebrew University, Jerusalem, Israel  
8 2. Buchmann Faculty of Law, Tel-Aviv University, Israel  
9 3. Department of Health Policy and Management, School of Public Health, Hebrew  
10 University, Jerusalem, Israel  
11 4. Phillip and Estelle Mizock Chair in Administrative and Criminal Law, The Faculty of  
12 Law, the Hebrew University, Jerusalem, Israel  
13 5. Department of Applied Mathematics, Israel Institute for Biological Research, Ness-  
14 Ziona, Israel

15

16 <sup>£</sup> All authors contributed equally to the manuscript

17

18 \* Corresponding author:

19 Address: Koret School of Veterinary Medicine, The Robert H. Smith Faculty of  
20 Agriculture, Food and Environment, The Hebrew University of Jerusalem, POB 12,  
21 Rehovot 76100, Israel.

22 Tel: 972-8-9489560. Fax: 972-8-9489634

23 E-mail: [eyal.klement@mail.huji.ac.il](mailto:eyal.klement@mail.huji.ac.il)

24

25

26 **Abstract**

27 **Background:**

28 The ongoing Covid-19 pandemic has driven many countries to take radical suppression  
29 measures. While reducing mortality, these measures result in severe economic repercussions,  
30 and inhibit the development of herd immunity. Until an effective vaccine will be available,  
31 we propose an alternative approach, akin to avalanche control at ski resorts, a practice which  
32 intentionally triggers small avalanches in order to prevent a singular catastrophic one. Its  
33 main goal is to approach herd immunity faster than the current alternatives, with lower  
34 mortality rates and lower demand for critical health-care resources. According to this  
35 approach, individuals whose probability of developing serious health conditions is low (i.e.  
36 20-49 years old with no comorbidities) will be offered the option to be voluntarily exposed to  
37 the virus under controlled supervision, and will then be issued 'immunity certificates' if they  
38 are confirmed to have developed SARS-CoV-2 antibodies.

39 **Methods:**

40 Using a compartmental model we examine the implications of the controlled avalanche (CA)  
41 strategy over the population in Israel. We compare four scenarios: in two scenarios the CA  
42 program is applied to the low-risk population (with the rest of the population subject to  
43 mitigation measures), followed by mitigation for the entire population or by uncontrolled  
44 spread. These are compared to mitigated and uncontrolled scenarios without the CA program.  
45 We discuss the economic, ethical and public health implications of the CA strategy.

46 **Findings:**

47 We show that compared to mitigation of the entire population, the CA strategy reduces the  
48 overall mortality by 43%, reduces the maximum number of people in need for ICUs by 62%  
49 and decreases the time required for release of 50% of the low-risk population by more than 2  
50 months.

51 **Interpretation:**

52 This study suggests an ethically acceptable practice, that enables reaching herd immunity  
53 faster than the current alternatives, with low mortality and minimal economic damage.

54

55

56

57 **Introduction**

58 The ongoing Covid-19 pandemic has created a crisis where optimal control and means of  
59 mitigation are still unknown. Two main competing strategies have been suggested and  
60 implemented for controlling the epidemic: The first, *suppression*, aims at drastic reduction of  
61 disease incidence. This strategy is based on radical social distancing, closure of schools and  
62 universities and forbidding mass gatherings. Policies reflecting this strategy were first  
63 enacted by the Chinese government and, subsequently, by other countries. The second  
64 strategy, *mitigation*, is based on case isolation, voluntary home quarantine, and social  
65 distancing of high-risk populations. This strategy was successfully implemented in Israel  
66 during the first three weeks of the epidemic. However, it was abandoned and replaced by a  
67 suppression strategy due to a sharp increase of disease incidence following a holiday (1).  
68 Mitigation strategy was also practiced for a short time in England before being abandoned  
69 after Ferguson et al. demonstrated their projections (2) and it is currently practiced in  
70 Sweden.

71 Ferguson et al., (2) demonstrated that although mitigation would reduce peak critical health  
72 care demand, it would still be several times higher than its surge capacity. Consequently, it  
73 would result in a staggering death toll. These grim forecasts were realized in the epidemics in  
74 Italy, Spain, France and the US, which shifted to suppression only during late stages of the  
75 epidemic. Suppression, on the other hand, though effective in controlling the epidemic, would  
76 prevent the development of herd immunity and is expected to paralyze the economy and  
77 carries far-reaching social ramifications.

78 Some countries (e.g. Taiwan, South-Korea and Singapore) have followed WHO  
79 recommendations (3), and implemented social distancing with contact tracing accompanied  
80 by massive testing and isolation of the infected prior to symptoms. These countries have been  
81 relatively successful in mitigating the epidemic and reducing case fatality so far (4) , though  
82 none of them has eliminated the virus.

83 Covid-19 is characterized by a high  $R_0$ , probable infectiousness of asymptomatic and pre-  
84 clinical patients (5), and has no known cure, precluding containment (6). Therefore, in the  
85 absence of effective vaccine, the only foreseeable endpoint of this epidemic can be expected  
86 when a certain level of herd immunity is reached. Such a condition requires a large  
87 proportion of the population (58%-70%) to be infected, depending on the estimated  $R_0$  (2.4-  
88 3.3) (2, 7). The main goal of any control strategy should be therefore to reduce the

89 percentage of high-risk population among those infected until herd immunity is reached, and  
90 use critical health care resources optimally over time.

91 The strategy we propose is based on identifiable risk characteristics of different segments in  
92 the population and on voluntary immunization through exposure. Instead of using non-  
93 discriminating measures targeted at the population as a whole, we propose regulated  
94 voluntary exposure of its low-risk members. Once they are certified as immune, these  
95 individuals return to the population, increase its overall immunity and resume their normal  
96 life. This approach is akin to avalanche control at ski resorts, a practice which intentionally  
97 triggers small avalanches in order to prevent a singular catastrophic one. Its main goal is to  
98 create herd immunity, faster than current alternatives, and with lower mortality rates and  
99 lower demand for critical health-care resources. Furthermore, it is also expected to be  
100 effective in relieving the huge economic pressures created by the current pandemic (For  
101 similar proposals see supplementary material).

102 Using a compartmental model of the SEIRD framework we examine three main effects of the  
103 proposed strategy: total mortality, impact on the ICU at the peak of the epidemic and time of  
104 return to work. We show that all three variables are significantly reduced by the proposed  
105 strategy. We then discuss the economic, ethical and distributional aspects of its  
106 implementation. We conclude that in the current situation, this approach is reasonable on all  
107 grounds and that its underlying premises should be further examined to allow its  
108 implementation.

109

## 110 **Materials and methods**

### 111 1. **The Proposed Approach: Regulated Voluntary Exposure Based on Risk Characteristics**

#### 112 A. Underlying modelling assumptions

113 The proposed strategy dynamics was modeled, based on three assumptions:

114 The first assumption is that people infected by SARS-CoV-2 become immunized to future re-  
115 infection for a long time period. Previous studies demonstrated a sustained neutralizing  
116 antibody activity, lasting for at least two years, after the onset of symptoms in most of SARS-  
117 Cov-1 recovered patients (8, 9) and persistence of anti-SARS-Cov-1 IgG in infected health-  
118 care workers for at least 12 years (10). In a recent study researchers failed to re-infect

119 Macaque monkeys 28 days after first clinical infection, indicating protective immunity  
120 developed after infection by SARS-Cov-2(11).

121 The second assumption, based on experience with SARS-Cov-2 is that the period of  
122 infectiousness is limited and that virus shedding can be easily detected. Data collected so far  
123 suggest that virus shedding by moderately affected Covid-19 patients does not exceed 14  
124 days after onset of clinical signs (12, 13). Virus shedding was documented in asymptomatic  
125 patients for at least seven days (14). Though there is no documentation of the longest period  
126 of virus shedding in asymptomatic patients it is very reasonable to conclude that they do not  
127 shed the virus longer than cases who show clinical signs. In accordance with this evidence,  
128 the current guidelines of the ECDC and other health agencies for hospital discharge are based  
129 on resolution of clinical signs (i.e. no fever for at least 3 days and significant improvement of  
130 respiratory symptoms combined with at least two negative consecutive respiratory tract  
131 samples taken at least 24 hours apart (14)).

132 The third assumption is that case fatality among people aged 20-49 years is very low.  
133 According to Verity et al. the proportions of cases hospitalized among patients aged 20-29,  
134 30-39 and 40-49 in China were 1%, 3.4% and 4.3%, respectively. Case fatality ratios (CFR)  
135 estimated for these ages in Wuhan were 0.03%, 0.08% and 0.16% respectively (15). Similar  
136 age specific CFRs were reported in South-Korea. Though Verity et al. did account for age  
137 differential under-ascertainment and the Korean data is based on very meticulous  
138 surveillance, the real extent of under-ascertainment may be lower and can be estimated only  
139 after availability serologic data. It should also be considered that these case fatalities include  
140 patients with co-morbidities even in the younger ages.

#### 141 B. Regulated voluntary exposure program

142 Given the above three assumptions, the following program is suggested: Individuals whose  
143 probability of developing serious health conditions is low will be offered the option to be  
144 exposed to the virus under controlled supervision. To do so, a threshold risk factor should be  
145 determined, based on easily identifiable and verifiable characteristics, most significantly age,  
146 but also the existence of other comorbidities such as hypertension, cardiac disease, lung  
147 disease, diabetes, etc.. Individuals whose risk is lower than this threshold would be allowed to  
148 participate in the voluntary exposure program.

149 Exposure may be applied using one of various alternative measures – either through  
150 individual controlled infection, or (as modelled here) through coordinated group exposure to

151 the virus and quarantine, where all participants can communicate and contract the virus, thus  
152 raising the effective reproductive number within this group. It may also be implemented by  
153 simply relaxing social distancing and other limitations for the participants, subject to  
154 subsequent quarantine and periodical medical monitoring.

155 The state would issue 'immunity certificates' to everyone who is confirmed to have developed  
156 SARS-CoV-2 antibodies and is verified as non-contagious (16) (development and validation  
157 of good serological assays to detect exposure to the virus is currently defined as a major need  
158 (4) and its wide implementation is a matter of short time). Certified individuals would be  
159 allowed to reenter society and the workforce, as they can no-longer infect other people. They  
160 may also provide medical treatment, as well as other necessary services to high-risk  
161 population. These certified individuals would resume their social and economic life, and  
162 contribute to the recovery of the economy on both supply and demand sides.

## 163 2. Modeling the epidemiological impact:

164 The dynamics of the COVID-19 epidemic spread as well as the effect of the controlled  
165 avalanche (CA) program were ascertained using a deterministic compartmental model which  
166 is an expansion of an earlier model (1). Similar to other models that describe the dynamics of  
167 COVID-19 in a given population, it describes the stages of the epidemic in a SEIRD  
168 framework (17-19). In this framework, the modeled population is divided into five  
169 compartments: S – susceptible, E – exposed and asymptomatic, I – infectious and  
170 symptomatic, R – recovered and immune, and D – deceased. As there is evidence for the  
171 possibility of infection by asymptomatic COVID-19 cases (5) the model consists the  
172 possibility that a fraction  $\varepsilon_E$  of the individuals in the E compartment can be infectious.

173 Due to the fact that the risk of mortality due to COVID-19 is associated with age (15), the  
174 model divides the population into two sub-populations: the low-risk labor age population that  
175 consists of individuals whose age is in the range of 20-49 and the general population which  
176 consists of all other individuals (top and middle SEIRD chains in Fig. 1, correspondingly).

177 The low-risk and general population lead to separate dynamics. However, these two sub-  
178 populations are connected by the same group of infectious individuals,  $T_I$ , which consists of  
179 all members of the infectious and symptomatic compartments in the general and low-risk  
180 population (namely, I and  $I_L$  in Fig. 1) as well as a fraction  $\varepsilon_E$  of the asymptomatic members  
181 of the two populations (namely, E and  $E_L$  in Fig. 1). Therefore, the susceptible individuals in  
182 each of the sub-populations (namely, S and  $S_L$ ) can be infected by any infectious individual

183 from either sub-population. The disease transmission (i.e., the passage from the S to E and  $S_L$   
184 to  $E_L$ ) depends also on the effective contact rate,  $\beta$ .

185 Following the infection, the passage of asymptomatic cases to symptomatic (i.e., from the E  
186 to I and from the  $E_L$  to  $I_L$  compartments) is dictated by the rate of development of clinical  
187 symptoms. From there, symptomatic and infectious individuals can either recover or die from  
188 the disease, according to the CFR of the general population or that of the low-risk population,  
189  $\delta$  and  $\delta_L$ , correspondingly. The passage between the I to the D or R (or from  $I_L$  to  $D_L$  and  $R_L$ )  
190 compartments is dictated by the recovery rate,  $\gamma$ .

191 In the model the CA program is implemented by allowing volunteers to stay with other  
192 infected individuals at the same residency (e.g. hotels designated for the CA program), in  
193 which no social distancing is implemented and high contact rate is allowed. When the CA  
194 program is activated (low SEI chain in Fig. 1), a batch process begins. The function  $v(t)$  is a  
195 forcing function that every  $\tau$  days returns a value of 1, thus allowing a new batch (whose size  
196 is  $N_A$ ) of low-risk susceptible volunteers to join the CA program. In the CA program, the  
197 infection of susceptible volunteers,  $S_A$ , is dictated by  $T_A$ , the group of infectious individuals  
198 among the CA program volunteers and  $\beta_A$ , the effective contact rate in the program. Upon  
199 recovery or death, the volunteers return to the  $R_L$  and  $D_L$  compartments of their original  
200 population.

201 In this study, the parameters that describe the epidemiology of the COVID-19 disease,  
202 namely  $\kappa$  and  $\gamma$ , were based on an analysis of actual event-data (20). The infection fatality  
203 ratios,  $\delta$  and  $\delta_L$ , were based on weighted average of data on Israel's population by age groups  
204 with age dependent COVID-19 CFRs (15, 21). The periodic batch size of the CA program  
205 volunteers was determined by associated data on the inventory of active tourist hotel rooms in  
206 Israel (22). The effective contact rates,  $\beta$  and  $\beta_A$  were set according to parameters estimated  
207 for data from the COVID-19 outbreak in China, before and during control measures were  
208 taken (23, 24). Further details on the model and its parameters are provided in the  
209 supplementary part.

210 The dynamics of epidemic spread was modeled considering two distinct populations: low-  
211 risk (ages of 20 to 49) and the rest of the population, termed here the general population (ages  
212 0-19 and 50-). The following four scenarios were simulated:

213 1. Uncontrolled epidemic spread for the entire population.

- 214 2. Mitigated epidemic spread for the entire population
- 215 3. CA program for the low-risk population with mitigation for the general population,  
216 followed by mitigation for the entire population.
- 217 4. CA program for the low-risk population with mitigation for the general population,  
218 followed by followed by uncontrolled spread.
- 219

## 220 **Results**

221 In the modeled AC scenarios, the program was active during 210 days. During this time, the  
222 simulation included an AC participation ratio of 81.5% from the low-risk population. As  
223 depicted in Table 1, implementation of the CA policy leads to a dramatic reduction in  
224 mortality, which is accompanied by a significantly faster release of the labor population. In  
225 all scenarios, the main source of mortality is the general population. Fig. 2 demonstrates that  
226 the CA policy is fastest in releasing the lower risk - labor population, and it results in the  
227 lowest infection rate among the higher risk - general population.

228 A crucial number in public health management is the number of the intensive care units  
229 (ICUs) available. A major challenge is to stay below this limit, which is currently in Israel  
230 2,864 ICUs (25). Fig. 3 shows the ICU hospitalization demand for the four scenarios stated  
231 above, where the current limit of ICUs in Israel is marked by horizontal grey dashed line. The  
232 two scenarios which include CA implementation exhibit dramatically lower cases in need of  
233 ICU hospitalizations. Furthermore, the maxima for the general population in need for ICUs  
234 under both CA scenarios is 4,146 cases (and 570 for the low risk population), much lower  
235 than the 11,839 and 35,382 cases for mitigation and uncontrolled scenarios, respectively  
236 (Table 1).

237 Although in all scenarios the number of ICU hospitalizations for the total population exceeds  
238 the ICU limit in Israel, the magnitude of the surge is dramatically reduced when the CA  
239 strategy is implemented. Notably, in all scenarios, the general population is the main source  
240 for the ICU demand while the CA volunteers require only very low percentage of the ICU  
241 maximal capacity. It should also be pointed out that the analysis is based on the median  
242 effective contact rate over 29 provinces, which implemented moderate lockdown in China  
243 during early stages of the epidemic (23). More effective lockdown measures as implemented  
244 later in China should lead to lower estimates of morbidity and mortality.

245



246

247 **Discussion**

248 In this current reality created by the ongoing Covid-19 epidemic, it is imperative to explore  
249 different new control strategies and to rationally evaluate their costs, risks and benefits  
250 compared to existing strategies. The proposed CA strategy is not intended to substitute  
251 suppression measures, which are extremely important for epidemic containment and  
252 prevention of overwhelming available ICU units (26); its efficient implementation is in  
253 conjunction with such measures, as early as possible during the initial phase of the epidemic,  
254 or as an exit strategy after the initial epidemic has been contained.

255 Our analysis shows that implementation of the CA strategy is expected to significantly reduce  
256 the consequent death toll, to prevent overload of the ICU units through faster formation of  
257 overall herd immunity in the population, and to significantly reduce the time period of  
258 economic paralysis. The age dependent CFR used in this study does not separate sub-  
259 populations with comorbidities. It can be expected that exclusion from the AC program of  
260 people that are on the eligible age but suffer from comorbidities, may result in much lower  
261 mortality among the volunteers. Furthermore, as the model demonstrates, the main strategy  
262 for preventing overload of the ICU, is to increase suppression measures on the general  
263 population, and not to limit the CA capacity, whose share of demand for ICU is low.  
264 Implementation of the CA policy is thus the safest among all the possible options.

265 Since implementation depends on voluntary exposure, behavioral, ethical and political  
266 considerations should also be considered. As we discuss in detail in the supplementary part,  
267 each individual's decision whether to join the CA program depends on his risk exposure and  
268 his individual earning and utility producing opportunities. An individual is more likely to join  
269 the program the lower his expected fatality rate from the virus, the higher his probability of  
270 contracting the virus if he does not join the program, the higher his benefit from resuming  
271 normal life, and the longer he expects the social and economic closure to remain in place.

272 Our model demonstrates that if 81.5% of people aged 20-49 participate in the program, the  
273 probability of contracting the virus for non-participants from the general population is 40% if  
274 mitigation measures and social distancing are not released after the CA is fully exhausted,  
275 and 71% if they are released. It also shows that the CA program is almost fully exhausted  
276 after 200 days. If mitigation measures and social distancing are lifted immediately following  
277 the end of the program, this implies that anyone not joining the program expects to lose

278 earning opportunities for this period of time. The two variables – alternative risk of exposure  
279 to the virus, and time before resumption of normal life – affect the decision whether to join  
280 the program. As we explain in the supplementary part, there is some rational expectations  
281 equilibrium, such that all people who may join the program, actually choose to do so. The  
282 maximum participation age established by such an equilibrium may prove lower than the one  
283 analyzed in the model – 50.

284 Moreover, ethical considerations (also presented in the supplement) may further require  
285 lowering the maximum age for participation in the program. Since exposure under the  
286 program is voluntary, consent-based criteria support the exposure of young people.  
287 Furthermore, since exposed people are isolated, and once they recover and become immune,  
288 they rejoin the general population, their exposure reduces negative externalities to other  
289 people, and hence public health (and furthermore, social welfare) concerns also support their  
290 exposure. The remaining concern is whether the state should impose a limitation on voluntary  
291 assumption of risk, due to paternalistic considerations. These considerations do establish a  
292 maximum level of risk – or maximum age, above which voluntary exposure cannot be  
293 justified. It may therefore well be that the demand for participation in the program would  
294 exceed the maximum age allowed. The implementation problem may then be how to prevent  
295 higher risk individuals from independently contracting the virus.

296 To implement CA, governments must have the political will to commit to a program that  
297 combines isolation/closure with voluntary exposure for a pre-defined time period. Given  
298 extreme suppression measures that governments have implemented, it would seem reasonable  
299 that controlled, voluntary exposure could be managed. Rather than opening businesses and  
300 public spaces to all low risk groups, thus risking uncontrolled disease spread including to  
301 vulnerable populations, governments can leverage success in suppression policies to move to  
302 a CA program.

303 Implementation of the program does not imply that professional personnel will infect people  
304 similar to challenge studies. Rather, the government can provide the tools and environment  
305 for whoever likes to contract infection to perform it easily and in a regulated manner.  
306 Suppression resources may be turned to enforcement of rules regarding screening of applicant  
307 volunteers, monitoring mechanisms and patterns of infection, recovery and immunity among  
308 volunteers and their social contacts, and regulation of “immunity certification”.

309 Transparent information regarding CA policy, its uptake, and case studies of volunteers'  
310 experiences should be provided to the public, the media and, in particular, target groups for  
311 voluntary exposure. The public, which in many countries has demonstrated its ability to  
312 understand and adhere to pandemic related information and edicts, must understand, as much  
313 as possible, the risks and benefits of CA to both individuals and society. It would seem they  
314 are currently primed to do so (27).

315 While the anticipated morbidity and mortality among volunteers for CA is expected to be  
316 lower than other routinely undertaken risks, government should offer suitable recognition and  
317 compensation to volunteers who suffer health setbacks and to their families in case of  
318 mortality due to participation. Participants in the program may also be offered to volunteer  
319 for studies exploring important questions such as the length of protective immunity. Plasma  
320 donated by recovered patients can be used to treat critically ill Covid-19 patients (28, 29).  
321 The program may be later adjusted for recruiting volunteers to challenge studies, enhancing  
322 the licensure of vaccines, a practice that was recently suggested by several leading scientists  
323 and was claimed to be ethically justified in the current situation (30).

324 Elimination of this particular threat cannot materialize until adequate herd immunity is  
325 reached. It is therefore time for policy makers to include herd immunity as the main goal in  
326 the array of policy options. The health, economic, and social costs of all the options to  
327 achieve this goal need to be more fully evaluated, compared and discussed. These  
328 considerations must include the avoidance of getting stuck in one policy direction, sober  
329 confronting of the ethical concerns regarding societal attitudes towards risk taking and more  
330 complete assessment of the tradeoffs among health impact, economic impact and social  
331 capital. This will require a multi sector, professional and representative task force to manage  
332 policy options such as CA and the Covid-19 crisis in general.

333

334 TABLE I. Statistical parameters of the examined scenarios, regarding the general population  
 335 and the low-risk labor-age population. The scenarios are: 1 -Without lockdown, 2 – effective  
 336 lockdown, 3 – Controlled avalanche (CA) program during lockdown, 4 - CA program during  
 337 an ongoing lockdown. At the program end, the lockdown is lifted.


Parameter	Description	Units	Scenario 1	Scenario 2	Scenario 3	Scenario 4
Number of deceased	General population	People	64,299	48,426	26,405	47,566
	Low-risk Population	People	2,666	2,008	2,545	2,538
	Total population	People	66,965	50,434	28,950	50,104
Maximal number of patients requiring critical care	General population	People	35,382	11,839	4,146	4,146
	Low-risk population	People	1,490	498	570	570
	Total population	People	36,872	12,337	4,716	4,716
Time of recovery of a given fraction of the low-risk population	Quarter	Days	79	181	87	87
	Half	Days	94	226	142	142
	Three quarters	Days	112	-	197	197
Fraction of population infected by Covid-19	General population	Percent	96	73	40	71
	Low-risk population	Percent	96	73	92	96

338

339

340

341



342

343

344 **FIG. 1.** Schematic flow diagram for the Avalanche model. The model describes the Covid-19  
 345 dynamics in a given population, which is divided to five compartments: S – Susceptible, E –  
 346 exposed, I – Infectious, R – Recovered and immune, D – Deceased. The population is divided  
 347 to two: The general population (ages 0-19 and 50-) and the low-risk labor-age population  
 348 (ages 20-49), that is indicated by L subscript. From the L population volunteers are recruited  
 349 to the controlled avalanche program that is indicated by A subscript.

350

351

352

353

354


355

356

357

358


359



360 **FIG. 2.** The percentage of recovered cases in three scenarios, in red uncontrolled, in blue  
361 mitigation and in black the controlled avalanche strategy. In the left side for the general  
362 population and in the right side for the low risk population.

363

364



365

366 **FIG 3.** The dynamics of cases in need ICUs for four scenarios: Scenario 1- uncontrolled,  
367 Scenario 2 – mitigation, Scenario 3 - controlled avalanche (CA) program, followed by  
368 mitigation, Scenario 4 - CA program, followed by uncontrolled policy. The general  
369 population is in blue line and those from the low-risk population is in red line.

370

371 References :

- 372 1. Klausner Z, Fattal E, Hirsch E, Shapira SC. A single holiday was the turning point of the  
373 COVID-19 policy of Israel. medRxiv. 2020:2020.03.26.20044412.
- 374 2. Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9:  
375 Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and  
376 healthcare demand. Imperial College London; 2020.
- 377 3. Hamzelou J. We have to respect the coronavirus – and learn as the disease evolves 2020  
378 [updated 16/03/2020. Available from: [https://www.newscientist.com/article/2237493-  
379 we-have-to-respect-the-coronavirus-and-learn-as-the-disease-evolves/#ixzz6IBDr9uAO](https://www.newscientist.com/article/2237493-we-have-to-respect-the-coronavirus-and-learn-as-the-disease-evolves/#ixzz6IBDr9uAO).
- 380 4. Humanity tested. Nature Biomedical Engineering. 2020.
- 381 5. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier  
382 Transmission of COVID-19. JAMA. 2020.
- 383 6. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease  
384 outbreak controllable. Proc Natl Acad Sci U S A. 2004;101(16):6146-51.
- 385 7. Zhuang Z, Zhao S, Lin Q, Cao P, Lou Y, Yang L, et al. Preliminary estimating the  
386 reproduction number of the coronavirus disease (COVID-19) outbreak in Republic of  
387 Korea and Italy by 5 March 2020. medRxiv. 2020:2020.03.02.20030312.
- 388 8. Liu L, Xie J, Sun J, Han Y, Zhang C, Fan H, et al. Longitudinal profiles of  
389 immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus  
390 components and neutralizing activities in recovered patients. Scand J Infect Dis.  
391 2011;43(6-7):515-21.
- 392 9. Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody  
393 responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562-  
394 4.
- 395 10. Guo X, Guo Z, Duan C, Chen Z, Wang G, Lu Y, et al. Long-Term Persistence of IgG  
396 Antibodies in SARS-CoV Infected Healthcare Workers. medRxiv. 2020.
- 397 11. Bao L, Deng W, Gao H, Xiao C, J. L, Xue J, et al. Reinfection could not occur in SARS-  
398 CoV-2 infected rhesus macaques. medRxiv. 2020.
- 399 12. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019  
400 (COVID19). Geneva; 2020.
- 401 13. Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al.  
402 Clinical presentation and virological assessment of hospitalized cases of coronavirus  
403 disease 2019 in a travel-associated transmission cluster. medRxiv. 2020.



- 404 14. ECDC. Novel coronavirus (SARS-CoV-2). Discharge criteria for confirmed COVID-19  
405 cases – When is it safe to discharge COVID-19 cases from the hospital or end home  
406 isolation? . 2020.
- 407 15. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the  
408 severity of COVID-19 disease. *Lancet*. 2020:2020.03.09.20033357.
- 409 16. Wighton D, Chasan D. Germany will issue coronavirus antibody certificates to allow  
410 quarantined to re-enter society 2020 [Available from:  
411 [https://www.telegraph.co.uk/news/2020/03/29/germany-will-issue-coronavirus-antibody-](https://www.telegraph.co.uk/news/2020/03/29/germany-will-issue-coronavirus-antibody-certificates-allow-quarantined/)  
412 [certificates-allow-quarantined/](https://www.telegraph.co.uk/news/2020/03/29/germany-will-issue-coronavirus-antibody-certificates-allow-quarantined/).
- 413 17. Cao Z, Zhang Q, Lu X, Pfeiffer D, Jia Z, Song H, et al. Estimating the effective  
414 reproduction number of the 2019-nCoV in China. *medRxiv*. 2020:2020.01.27.20018952.
- 415 18. Read JM, Bridgen JR, Cummings DA, Ho A, Jewell CP. Novel coronavirus 2019-nCoV:  
416 early estimation of epidemiological parameters and epidemic predictions. *medRxiv*.  
417 2020:2020.01.23.20018549.
- 418 19. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and  
419 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a  
420 modelling study. *Lancet*. 2020;395(10225):689-97.
- 421 20. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al.  
422 Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus  
423 Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data.  
424 *J Clin Med*. 2020;9(2).
- 425 21. Statistical Abstract of Israel 2019 - No.70. [Internet]. 2019. Available from:  
426 [https://www.cbs.gov.il/en/publications/Pages/2019/Statistical-Abstract-of-Israel-2019-](https://www.cbs.gov.il/en/publications/Pages/2019/Statistical-Abstract-of-Israel-2019-No-70.aspx)  
427 [No-70.aspx](https://www.cbs.gov.il/en/publications/Pages/2019/Statistical-Abstract-of-Israel-2019-No-70.aspx).
- 428 22. Tourism and Hotel Services Statistics - Quarterly 4 2019. [Internet]. 2019. Available  
429 from: [https://www.cbs.gov.il/en/publications/Pages/2019/Tourism-and-Hotel-Services-](https://www.cbs.gov.il/en/publications/Pages/2019/Tourism-and-Hotel-Services-Statistics-Quarterly-4-2019.aspx)  
430 [Statistics-Quarterly-4-2019.aspx](https://www.cbs.gov.il/en/publications/Pages/2019/Tourism-and-Hotel-Services-Statistics-Quarterly-4-2019.aspx).
- 431 23. Maier BF, Brockmann D. Effective containment explains sub-exponential growth in  
432 confirmed cases of recent COVID-19 outbreak in Mainland China. *medRxiv*.  
433 2020:2020.02.18.20024414.
- 434 24. Tian H, Liu Y, Li Y, Wu C-H, Chen B, Kraemer MUG, et al. An investigation of  
435 transmission control measures during the first 50 days of the COVID-19 epidemic in  
436 China. *Science*. 2020:eabb6105.

- 437 25. Lis J. Israel Has Just 1,437 Ventilators in Reserve for Coronavirus Patients, Lawmakers  
438 Told. . Haaretz 2020 26/03/2020.
- 439 26. Flaxman S, Mishra S, Gandy A, Unwin H, Coupland H, Mellan T, et al. Report 13:  
440 Estimating the number of infections and the impact of nonpharmaceutical interventions  
441 on COVID-19 in 11 European countries. Imperial College London (30-03-2020).  
442 Imperial College London; 2020.
- 443 27. Arundhati Roy: “The Pandemic Is a Portal” 2020 [Available from:  
444 <https://conversations.e-flux.com/t/arundhati-roy-the-pandemic-is-a-portal/9812>.
- 445 28. Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and  
446 Challenges. JAMA. 2020.
- 447 29. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill  
448 Patients With COVID-19 With Convalescent Plasma. JAMA. 2020.
- 449 30. Eyal N, Lipsitch M, Smith PG. Human Challenge Studies to Accelerate Coronavirus  
450 Vaccine Licensure (Preprint). DASH. 2020.

451